UG’s Prof. Yvonne Dei-Adomakoh Presents Paper at ASH 2024 Conference
As the University continues to make great strides in its quest to undertake impactful research, a research paper by Prof. Yvonne Dei-Adomakoh, the Acting Dean of the University of Ghana Medical School, has been accepted for a presentation at the 66th American Society of Hematology’s (ASH) Annual Conference.
Prof. Dei-Adomakoh’s study, Double-Blind, Placebo-Controlled Randomized Controlled Trial of Hydroxyurea for HbSC: Results of the Prospective Identification of Variables as Outcomes for Treatment (PIVOT) Trial, revealed that Hydroxyurea shows benefits for managing hemoglobin SC (HbSC), a form of Sickle Cell Disease (SCD). Hydroxyurea is a daily oral medication that can reduce SCD symptoms by helping red blood cells maintain a healthy shape.
“Hydroxyurea comes at a low cost; in Ghana it’s on our national health insurance,” said Prof. Dei-Adomakoh. “If we see safety and efficacy in a multicenter phase III trial, I think that countries should push for it to be on their national health insurance and be readily available at very low cost to patients with SCD.”
ASH is the world's largest professional society with more than 18,000 clinicians and scientists members from nearly 100 countries who are working to conquer blood diseases. Its mission is to foster high-quality, equitable care, transformative research, and innovative education to improve the lives of patients with blood and bone marrow disorders.
Congratulations to Prof. Dei-Adomakoh on achieving this feat!
Read more here: https://www.hematology.org/newsroom/press-releases/2024/researchers-report-new-opportunities-to-improve-quality-of-life